Charles River Laboratories International Return on Equity (ROE) Growth & History (CRL)

Charles River Laboratories International's return on equity was −4.36% for fiscal 2025.

View full Charles River Laboratories International company overview

Charles River Laboratories International annual return on equity history

Charles River Laboratories International annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-27−4.36%−4.99 pp
20242024-12-280.63%−13.81 pp
20232023-12-3014.44%−3.20 pp
20222022-12-3117.65%+0.83 pp
20212021-12-2516.82%−2.62 pp
20202020-12-2619.43%+2.36 pp
20192019-12-2817.07%−2.09 pp
20182018-12-2919.16%+6.05 pp
20172017-12-3013.11%−6.61 pp
20162016-12-3119.72%−1.53 pp
20152015-12-2621.25%+1.95 pp
20142014-12-2719.30%+2.73 pp
20132013-12-2816.56%−0.82 pp
20122012-12-2917.38%−0.76 pp
20112011-12-3118.13%+50.78 pp
20102010-12-25−32.64%−41.39 pp
20092009-12-268.75%

Charles River Laboratories International return on equity trends

Over the last five fiscal years, Charles River Laboratories International's return on equity decreased from 19.43% to −4.36%, a change of −23.79 percentage points. The latest reported quarter, Q2 2026, shows −0.05%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Charles River Laboratories International source filings ↗

Community posts

It’s quiet here.

No posts about CRL yet. Start the conversation.

Write the first post